Memantine for treatment of moderate to severe Alzheimer's disease

Area of Science:

• Neuroscience
• Pharmacology
• Geriatrics

Background:

• Alzheimer's disease (AD) is a progressive neurodegenerative disorder.
• Current treatments offer limited efficacy, especially in moderate to severe stages.
• Memantine is an NMDA receptor antagonist with potential therapeutic benefits.

Purpose of the Study:

• To evaluate the efficacy and safety of memantine for treating moderate to severe Alzheimer's disease.
• To assess memantine's impact on activities of daily living, cognition, and global performance.
• To review evidence supporting Health Canada's Notice of Compliance with conditions (NOC/c) for memantine.

Main Methods:

• Two randomized controlled trials (RCTs) involving 656 patients over 24-28 weeks.
• A post hoc subgroup analysis of 79 patients with severe AD from a 12-week trial.
• Assessment of outcomes including activities of daily living, cognition, and global performance.

Main Results:

• Memantine, alone or with donepezil, showed improvements in activities of daily living and cognition.
• No significant improvements were observed in global performance scores.
• Memantine is the only available drug for severe AD, with potential for off-label use.

Conclusions:

• Memantine demonstrates a relative benefit in specific domains for moderate to severe Alzheimer's disease.
• The drug's rapid diffusion rate and unique indication for severe AD warrant further investigation.
• Health Canada's conditional approval highlights the need for continued evidence generation.